Авторы

  • Абдуллаева Ч.А., Жураев М.И.

Ключевые слова:

ишемическая болезнь сердца, сахарный диабет 2 типа, полигенная шкала риска, GLUL, 9p21, гаптоглобин, микроРНК, длина теломер, прогноз.

Библиографические ссылки

1. Sarwar N, Gao P, Seshasai SR, et al.; Emerging Risk Factors Collaboration. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010;375(9733):2215-2222. DOI:10.1016/S0140-6736(10)60484-9.

2. Marx N, Federici M, Schütt K, Müller-Wieland D, Ajjan RA, Antunes MJ, et al. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023;44(39): 4043-4140. DOI:10.1093/eurheartj/ehad192.

3. Vrints C, Andreotti F, Koskinas KC, Rossello X, Adamo M, Ainslie J, et al. 2024 ESC Guidelines for the management of chronic coronary syndromes. Eur Heart J. 2024;45(36):3415-3537. DOI:10.1093/ eurheartj/ehae177.

4. Lee H, Fernandes M, Lee J, Merino J, Kwak SH. Exploring the shared genetic landscape of diabetes and cardiovascular disease: findings and future implications. Diabetologia. 2025;68(6):1087-1100. DOI:10.1007/s00125-025-06403-9.

5. Khera AV, Chaffin M, Aragam KG, Haas ME, Roselli C, Choi SH, et al. Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations. Nat Genet. 2018;50(9):1219-1224. DOI:10.1038/s41588-018-0183-z.

6. Patel AP, Wang M, Ruan Y, Koyama S, Clarke SL, et al. A multi-ancestry polygenic risk score improves risk prediction for coronary artery disease. Nat Med. 2023;29(7):1793-1803. DOI:10.1038/s41 591-023-02429-x.

7. Morieri ML, Gao H, Pigeyre M, et al. Genetic tools for coronary risk assessment in type 2 diabetes: a cohort study from the ACCORD clinical trial. Diabetes Care. 2018;41(11):2404-2413. DOI:10.2337/dc 18-0709.

8. Qi L, Qi Q, Prudente S, et al. Association between a genetic variant related to glutamic acid metabolism and coronary heart disease in individuals with type 2 diabetes. JAMA. 2013;310(8):821-828. DOI:10.1001/jama.2013.276305.

9. Prudente S, Shah H, Bailetti D, et al. Genetic variant at the GLUL locus predicts all-cause mortality in patients with type 2 diabetes. Diabetes. 2015; 64(7):2658-2663. DOI:10.2337/db14-1653.

10. Look AHEAD Research Group. Prospective association of GLUL rs10911021 with cardiovascular morbidity and mortality among individuals with type 2 diabetes: the Look AHEAD study. Diabetes. 2016;65(1):297-302. DOI:10.2337/db15-0890.

11. Doria A, Wojcik J, Xu R, et al. Interaction between poor glycemic control and 9p21 locus on risk of coronary artery disease in type 2 diabetes. JAMA. 2008;300(20):2389-2397. DOI:10.1001/jama.2008. 649.

12. Shah HS, Gao H, Morieri ML, et al. Genetic predictors of cardiovascular mortality during intensive glycemic control in type 2 diabetes: findings from the ACCORD clinical trial. Diabetes Care. 2016;39(11):1915-1924. DOI:10.2337/dc16-0285.

13. Levy AP, Hochberg I, Jablonski K, et al. Haptoglobin phenotype is an independent risk factor for cardiovascular disease in individuals with diabetes: the Strong Heart Study. J Am Coll Cardiol. 2002;40 (11):1984-1990. DOI:10.1016/S0735-1097(02)025 34-2.

14. Cahill LE, Levy AP, Chiuve SE, Jensen MK, Wang H, Shara NM, et al. Haptoglobin genotype is a consistent marker of coronary heart disease risk among individuals with elevated glycosylated hemoglobin. J Am Coll Cardiol. 2013;61(7):728-737. DOI: 10.1016/j.jacc.2012.09.063.

15. Asleh R, Briasoulis A, Berinstein EM, et al. Meta-analysis of the association of the haptoglobin genotype with cardiovascular outcomes and the pharmacogenomic interactions with vitamin E supplementation. Pharmgenomics Pers Med. 2018; 11: 71-82. DOI:10.2147/PGPM.S159454.

16. Zampetaki A, Kiechl S, Drozdov I, Willeit P, Mayr U, Prokopi M, et al. Plasma microRNA profiling reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes. Circ Res. 2010;107(6): 810-817. DOI:10.1161/CIRCRESAHA.110.226357.

17. Zampetaki A, Willeit P, Tilling L, Drozdov I, Prokopi M, Renard JM, et al. Prospective study on circulating microRNAs and risk of myocardial infarction. J Am Coll Cardiol. 2012;60(4):290-299. DOI:10.1016/j.jacc.2012.03.056.

18. Cao L, Pan X, Li Y, Jia W, Huang J, Liu J. Predictive value of circulating miR-409-3p for major adverse cardiovascular events in patients with type 2 diabetes mellitus and coronary heart disease. Endocrinol Diabetes Nutr (Engl Ed). 2024;71(9):372-379. DOI: 10.1016/j.endien.2024.11.002.

19. Haycock PC, Heydon EE, Kaptoge S, Butterworth AS, Thompson A, Willeit P. Leucocyte telomere length and risk of cardiovascular disease: systematic review and meta-analysis. BMJ. 2014;349: g4227. DOI:10.1136/bmj.g4227.

20. Yang CH, Huang MLH, Davis WA, Jenkins AJ, Davis TME. Determinants of temporal change in telomere length and its associations with chronic complications and mortality in type 2 diabetes: the Fremantle Diabetes Study Phase II. Cardiovasc Diabetol. 2025; 24:267. DOI:10.1186/s12933-025-02 832-3.